Cover Image
市場調查報告書

減肥藥、治療:技術、全球市場

Obesity Drugs and Therapies: Technologies and Global Markets

出版商 BCC Research 商品編碼 357987
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
Back to Top
減肥藥、治療:技術、全球市場 Obesity Drugs and Therapies: Technologies and Global Markets
出版日期: 2016年05月18日 內容資訊: 英文 176 Pages
簡介

全球肥胖治療市場規模,預計從2016年到2021年以12.7%的年複合成長率發展,從2016年的約43億美元到2021年達78億美元以上。

本報告提供全球肥胖治療市場相關調查,減肥藥、治療、相關技術概要,世界市場趨勢分析,肥胖症治療手術分析,減肥藥、手術相關資訊,市場動態的評估,產業結構與市場環境分析,及主要企業簡介等資訊。

第1章 簡介

第2章 摘要整理

第3章 肥胖概要、背景

  • 肥胖的說明
  • 肥胖中包含的生物化學
  • 肥胖的原因
  • 相關症狀
  • 腸促胰島素的利用的相關資料
  • 肥胖的GLP-1未來

第4章 市場概要、預測

  • 整體醫藥品市場
  • 銷售領域的糖尿病
  • 生技藥品及GLP-1受體促效劑的製造
  • 生技藥品情勢
  • 醫藥品形勢中的肥胖治療
  • 市場環境
  • 肥胖市場上契約
  • 減肥藥的簡歷
  • 近幾年趨勢及肥胖治療的認證
  • 手術轉換期
  • 減重手術的點閱存取
  • 胃束帶、球囊詳細內容
  • 束帶一部分的球囊
  • 手術利用、支出

第5章 開發平台詳細內容

  • 設備認證流程
  • FDA臨床實驗的優點/風險模型
  • 減肥藥朝向FDA
  • 專利
  • 開發平台

第6章 企業簡介

  • ALLURION TECHNOLOGIES
  • A.M.I. GMBH AUSTRIA
  • AMUNIX
  • APOLLO ENDOSURGERY INC.
  • ARENA PHARMACEUTICALS INC.
  • ARISAPH
  • ASPIRE BARIATRICS INC.
  • ASTRAZENECA
  • ATHERSYS INC.
  • BARONOVA INC.
  • BECTON, DICKINSON AND CO.
  • BFKW
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CIRCUIT THERAPEUTICS INC.
  • CONJUCHEM
  • C.R. BARD INC.
  • DONG-A SOCIO HOLDINGS
  • EISAI
  • ELI LILLY AND CO.
  • EMISPHERE TECHNOLOGIES INC.
  • ENDOBETIX
  • ENDOSPHERE INC.
  • ENTEROMEDICS INC.
  • ETHICON ENDO-SURGERY LLC
  • GELESIS INC.
  • GI DYNAMICS INC.
  • GLAXOSMITHKLINE PLC
  • HANMI PHARMACEUTICAL CO. LTD.
  • HELIOSCOPIE
  • INTARCIA THERAPEUTICS INC.
  • INTRAPACE INC.
  • INTREXON CORP.
  • JOHNSON & JOHNSON
  • LIGAND PHARMACEUTICALS INC.
  • LIGHTLAKE THERAPEUTICS INC.
  • MANNKIND CORP.
  • MEDTRONIC
  • MERCK
  • MERRION PHARMACEUTICALS LTD.
  • METACURE GERMANY GMBH
  • MID-MEDICAL INNOVATION DEVELOPMENT
  • MITSUBISHI TANABE PHARMA CORP.
  • NEOTHETICS INC.
  • NGM BIOPHARMACEUTICALS INC.
  • NORGINE B.V.
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • OBALON THERAPEUTICS
  • ONCIOMED
  • ONO PHARMACEUTICALS
  • OPKO BIOLOGICS
  • ORAMED PHARMACEUTICALS
  • OREXIGEN
  • PALATIN TECHNOLOGIES INC.
  • PFIZER
  • PHASEBIO PHARMACEUTICALS INC.
  • PLENSAT INC.
  • RESHAPE MEDICAL INC.
  • RHYTHM
  • ROCHE
  • SANIONA
  • SANOFI
  • SATRX LLC
  • SCIENTIFIC INTAKE
  • SHIRE PHARMACEUTICALS INC.
  • SPATZ FGIA
  • SYMMETRY THERAPEUTICS INC.
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TRANSITION THERAPEUTICS INC.
  • TULIP MEDICAL
  • VALENTX
  • VIVUS INC.
  • VTV THERAPEUTICS INC.
  • W.L. GORE AND ASSOCIATES
  • ZAFGEN
  • ZEALAND PHARMA A/S
  • ZOSANO PHARMA CORP.
目錄
Product Code: HLC188A

REPORT HIGHLIGHTS

The global market for obesity treatments should reach over $7.8 billion by 2021 from over $4.3 billion in 2016 at a compound annual growth rate (CAGR) of 12.7% from 2016 to 2021.

This report provides:

  • An overview of the global markets for obesity drugs, therapies, and related technologies.
  • Analyses of global market trends, with data from 2014, 2015, estimates of 2016, and projects CAGRs through 2021.
  • Focus on therapies for obesity that are U.S. FDA approved or allowed through doctors' permission in the U.S., namely liposuction and bariatric surgery as well as FDA approved medications.
  • Bariatric surgery, broken down into four procedures: Gastric Bypass, Sleeve Gastrectomy, Adjustable Gastric Band, and Biliopancreatic Diversion with Duodenal Switch (BPD/DS).
  • Information covering obesity pharmaceuticals and surgeries, outlines of various drug and surgery types, a history of the market, and challenges and obstacles as well as those hurdles that have been overcome.
  • Evaluation of the market's dynamics, specifically growth drivers, inhibitors, and opportunities.
  • A look at the industry's structure, and the landscape of the market.
  • Profiles of major players in the field.

SCOPE OF REPORT

The scope of this study encompasses companies that are involved in obesity treatment and prevention of relapse into weight gain. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

ANALYST'S CREDENTIALS

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOAL AND OBJECTIVES
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • WHERE PROGRESS WAS
  • SUMMARY TABLE: GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, 2014-2021 ($ MILLIONS)
  • KEY DRIVERS
  • KEY CHALLENGES
  • KEY TRENDS

CHAPTER 3 - OBESITY OVERVIEW AND BACKGROUND

  • TABLE 1: BMI CATEGORIES
  • OBESITY EXPLAINED
    • TABLE 2: KEY ADIPOCYTOKINES AND MAIN EFFECTS
  • BIOCHEMISTRY INVOLVED IN OBESITY
    • FIGURE 1: MAIN SIGNALING AREAS TARGETED FOR OBESITY INTERVENTION
    • Neuropeptide Y (NPY) Inhibitors
    • Sympathomimetics
    • Tesofensine
    • Dopamine Antagonists
    • Cannabinoid-1 Receptor (CB1) Antagonists
    • Leptin
    • Bupropion
    • Zonisamide
    • Gastrointestinal Areas of Activity
      • Glucagon-like Peptide-1 Analogues
      • Monoacylglycerol Acyltransferase 2 (MGAT2)-Mediated Enzyme
      • Oxyntomodulin
      • PYY
      • CCK and CCK1R Agonists
      • Ghrelin and Ghrelin Inhibitors
      • Enterostatin and Apolipoprotein A-IV
      • Pancreatic Polypeptide (PP)
      • Amylin and Amylin Analogues
      • Lipase Inhibitors
      • Cyclic Nucleotides
  • OBESITY CAUSES
    • Age
    • Genetics
    • Pregnancy
    • Medications
    • Inadequate or Excessive Sleep
  • RELATED CONDITIONS
    • Polycystic Ovary Syndrome (PCOS)
    • Cardiovascular Disease
    • Cancer
    • Binge Eating
      • TABLE 3: MEDICATIONS IN DEVELOPMENT FOR BINGE EATING
    • Diabetes
      • Standard Diabetic Treatments
        • Metformin
        • Sulfonylurea (SU)
        • Thiazolidinedione (TZD)
        • Alpha-Glucosidase Inhibitors
        • Insulin Treatment
          • Long-Acting Insulin
          • Intermediate-Acting Insulin
          • Regular or Short-Acting Insulin
          • Rapid-Acting Insulin
            • FIGURE 2: ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
      • Incretin Therapies
        • TABLE 4: COMMERCIALIZED INCRETIN THERAPY
        • TABLE 5: ADVANTAGES TO ADDING INCRETIN THERAPY
        • Exenatide
        • Liraglutide
        • Dulaglutide
        • Albiglutide
        • Lixisenatide
  • DATA ON INCRETIN USE
    • FIGURE 3: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
  • GLP-1's Future in Obesity
    • TABLE 6: GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
    • TABLE 7: GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT

CHAPTER 4 - MARKET OVERVIEW AND FORECAST

  • OVERALL PHARMA MARKET
    • TABLE 8: REVENUE OF TOP PHARMA COMPANIES, 2014 ($ BILLIONS)
    • FIGURE 4: GLOBAL MARKET SHARE OF PHARMACEUTICAL DRUGS BY REGION, 2014 AND 2019
  • DIABETES AS SALES TERRITORY
  • BIOLOGICS AND GLP-1 RECEPTOR AGONIST PRODUCTION
    • GROWTH FACTORS
    • GENE THERAPY
    • RECOMBINANT PROTEINS
    • MONOCLONAL ANTIBODIES
  • BIOLOGIC LANDSCAPE
    • TABLE 9: BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
  • OBESITY TREATMENTS WITHIN THE PHARMA LANDSCAPE
  • MARKET LANDSCAPE
  • DEALS IN THE OBESITY MARKET
    • TABLE 10: KEY AGREEMENTS AROUND OBESITY TREATMENTS
  • BRIEF HISTORY OF OBESITY DRUGS
  • RECENT TRENDS AND OBESITY THERAPY APPROVALS
    • TABLE 11: TIMELINE OF OBESITY MEDICATION APPROVALS
    • FDA-APPROVED ANTI-OBESITY MEDICATIONS DESCRIBED
      • Desoxyephedrine
      • Phendimetrazine
      • Benzphetamine
      • Diethylpropion
      • Orlistat (Xenical)
      • Phentermine and Topiramate Extended-Release (Qsymia)
      • Lorcaserin Hydrochloride (Belviq)
      • Naltrexone and Bupropion Extended-Release Tablets (Contrave/Mysimba)
      • Liraglutide (Saxenda)
      • Cetilistat (Oblean-Approved in Japan Only)
        • TABLE 12: FDA-APPROVED LONGER-TERM ANTI-OBESITY MEDICATIONS' MECHANISM OF ACTION AND WEIGHT-LOSS STATISTICS IN CLINICAL TRIALS
        • FIGURE 5: NUMBER OF COMMERCIALIZED OBESITY DRUGS AND DEVICE THERAPEUTICS, 2016 AND 2021 (UNITS)
        • FIGURE 6: NUMBER OF COMMERCIALIZED BARIATRIC SURGERIES MINUS BANDS AND BALLOONS, 2016 AND 2021 (UNITS)
        • FIGURE 7: NUMBER OF COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)
        • FIGURE 8: GLOBAL MARKET FOR COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)
        • FIGURE 9: NUMBER OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)
        • FIGURE 10: GLOBAL MARKET OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)
    • WEIGHT LOSS THROUGH SURGERY
      • Gastric Bypass
      • Biliopancreatic Diversion with Duodenal Switch (BPD/DS) Gastric Bypass
      • Sleeve Gastrectomy
      • Adjustable Gastric Band
  • SURGERY OUTCOMES
    • TABLE 13: PROS AND CONS OF BARIATRIC SURGERY
    • FIGURE 11: FOUR MOST COMMON U.S. BARIATRIC PROCEDURES
    • TABLE 14: DIFFERENCES BETWEEN THE OBESITY SURGERIES
  • ACCESS TO WEIGHT-LOSS SURGERY
    • FIGURE 12: CASE MIX OF BARIATRIC SURGERIES IN THE U.S., 2014 (%)
  • GASTRIC BANDS AND BALLOONS DETAILED
    • TABLE 15: TIMELINE OF OBESITY DEVICE APPROVALS
    • Lap-Band Gastric Banding System
    • Realize Gastric Band
    • Maestro Rechargeable System
      • FIGURE 13: MAESTRO RECHARGEABLE SYSTEM
  • BALLOONS AS PART OF BANDS
    • ReShape Integrated Dual Balloon System
    • ORBERA Intragastric Balloon System
      • FIGURE 14: NUMBER OF COMMERCIALIZED OBESITY DEVICES*, 2016 AND 2021 (%)
  • SURGICAL USAGE AND SPENDING
    • TABLE 16: BARIATRIC SURGERY SPENDING IN EUROPE, 2012

CHAPTER 5 - DEVELOPMENT PIPELINE DETAILED

  • DEVICE APPROVAL PROCESS
  • BENEFIT/RISK MODEL FOR FDA CLINICAL TRIALS
    • TABLE 17: FDA BENEFIT-RISK ASSESSMENT FOR OBESITY DEVICE CLINICAL TRIALS
    • TABLE 18: TARGET EFFECTIVENESS LEVELS FOR TOTAL BODY WEIGHT LOST (TBL) (%)
  • MOVING OBESITY DRUGS THROUGH THE FDA
  • PATENTS
  • DEVELOPMENT PIPELINE
    • TABLE 19: OBESITY DRUGS IN DEVELOPMENT
    • KEY OBESITY DRUGS IN DEVELOPMENT
      • ZGN-440 (Beloranib)
      • Setmelanotide (RM-493)
      • Semaglutide (NN9536-GLP-1 Analogue)
      • HM11260C/Efpeglenatide (Glucagon-like Peptide-1 Analogue)
      • LAPSGLP/GCG-HM12525A (Glucagon-like Peptide-
      • Analogue/Glucagon Analogue)
      • ALS L1023 (Korean Clinical Trial)
      • ZP2929
      • PL-8905
      • Merck and NGM Biopharmaceuticals and NGM313, NGM386 and NGM395
      • MOD-6031 (Long-Acting Oxyntomodulin)
      • Tesofensine
      • Gelesis100
    • OBESITY DEVICES IN DEVELOPMENT
      • Obalon Therapeutics' Obalon balloon
      • Aspire Bariatrics' AspireAssist
      • SatiSphere System
      • Sensor Monitored Alimentary Restriction Therapy (SMART)
      • Spatz3 Adjustable Balloon
    • OTHER DEVICES
      • GI Dyamics' EndoBarrier
      • Allurion Technologies' Elipse Gastric Balloon
      • MetaCure's Diamond System
      • BAROnova's TransPyloric Shuttle (TPS)
    • DEVELOPMENT CASE STUDY: ZAFGEN
    • PROMISING NOVEL RESEARCH
    • OBESITY DRUGS IN EARLY RESEARCH
      • SYM401
      • Glycine-Beta Muricholic Acid (Gly-MCA)
      • Metformin
      • Miglitol
      • Fibroblast Growth Factor 21 (FGF21)
      • Amlexanox
      • p75 Neurotrophin Receptor (NTR)
      • Transcranial Direct Current Stimulation
      • Perforin and Dendritic Cells
        • TABLE 20: OBESITY DRUG AND DEVICE DEVELOPMENT RESOURCES

CHAPTER 6 - COMPANY PROFILES

  • ALLURION TECHNOLOGIES
  • A.M.I. GMBH AUSTRIA
  • AMUNIX
  • APOLLO ENDOSURGERY INC.
  • ARENA PHARMACEUTICALS INC.
  • ARISAPH
  • ASPIRE BARIATRICS INC.
  • ASTRAZENECA
  • ATHERSYS INC.
  • BARONOVA INC.
  • BECTON, DICKINSON AND CO.
  • BFKW
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CIRCUIT THERAPEUTICS INC.
  • CONJUCHEM
  • C.R. BARD INC.
  • DONG-A SOCIO HOLDINGS
  • EISAI
  • ELI LILLY AND CO.
  • EMISPHERE TECHNOLOGIES INC.
  • ENDOBETIX
  • ENDOSPHERE INC.
  • ENTEROMEDICS INC.
  • ETHICON ENDO-SURGERY LLC
  • GELESIS INC.
  • GI DYNAMICS INC.
  • GLAXOSMITHKLINE PLC
  • HANMI PHARMACEUTICAL CO. LTD.
  • HELIOSCOPIE
  • INTARCIA THERAPEUTICS INC.
  • INTRAPACE INC.
  • INTREXON CORP.
  • JOHNSON & JOHNSON
  • LIGAND PHARMACEUTICALS INC.
  • LIGHTLAKE THERAPEUTICS INC.
  • MANNKIND CORP.
  • MEDTRONIC
  • MERCK
  • MERRION PHARMACEUTICALS LTD.
  • METACURE GERMANY GMBH
  • MID-MEDICAL INNOVATION DEVELOPMENT
  • MITSUBISHI TANABE PHARMA CORP.
  • NEOTHETICS INC.
  • NGM BIOPHARMACEUTICALS INC.
  • NORGINE B.V.
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • OBALON THERAPEUTICS
  • ONCIOMED
  • ONO PHARMACEUTICALS
  • OPKO BIOLOGICS
  • ORAMED PHARMACEUTICALS
  • OREXIGEN
  • PALATIN TECHNOLOGIES INC.
  • PFIZER
  • PHASEBIO PHARMACEUTICALS INC.
  • PLENSAT INC.
  • RESHAPE MEDICAL INC.
  • RHYTHM
  • ROCHE
  • SANIONA
  • SANOFI
  • SATRX LLC
  • SCIENTIFIC INTAKE
  • SHIRE PHARMACEUTICALS INC.
  • SPATZ FGIA
  • SYMMETRY THERAPEUTICS INC.
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TRANSITION THERAPEUTICS INC.
  • TULIP MEDICAL
  • VALENTX
  • VIVUS INC.
  • VTV THERAPEUTICS INC.
  • W.L. GORE AND ASSOCIATES
  • ZAFGEN
  • ZEALAND PHARMA A/S
  • ZOSANO PHARMA CORP.

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: BMI CATEGORIES
    • TABLE 2: KEY ADIPOCYTOKINES AND MAIN EFFECTS
    • TABLE 3: MEDICATIONS IN DEVELOPMENT FOR BINGE EATING
    • TABLE 4: COMMERCIALIZED INCRETIN THERAPY
    • TABLE 5: ADVANTAGES TO ADDING INCRETIN THERAPY
    • TABLE 6: GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
    • TABLE 7: GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT
    • TABLE 8: REVENUE OF TOP PHARMA COMPANIES, 2014 ($ BILLIONS)
    • TABLE 9: BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
    • TABLE 10: KEY AGREEMENTS AROUND OBESITY TREATMENTS
    • TABLE 11: TIMELINE OF OBESITY MEDICATION APPROVALS
    • TABLE 12: FDA-APPROVED LONGER-TERM ANTI-OBESITY MEDICATIONS' MECHANISM OF ACTION AND WEIGHT-LOSS STATISTICS IN CLINICAL TRIALS
    • TABLE 13: PROS AND CONS OF BARIATRIC SURGERY
    • TABLE 14: DIFFERENCES BETWEEN THE OBESITY SURGERIES
    • TABLE 15: TIMELINE OF OBESITY DEVICE APPROVALS
    • TABLE 16: BARIATRIC SURGERY SPENDING IN EUROPE, 2012
    • TABLE 17: FDA BENEFIT-RISK ASSESSMENT FOR OBESITY DEVICE CLINICAL TRIALS
    • TABLE 18: TARGET EFFECTIVENESS LEVELS FOR TOTAL BODY WEIGHT LOST (TBL) (%)
    • TABLE 19: OBESITY DRUGS IN DEVELOPMENT
    • TABLE 20: OBESITY DRUG AND DEVICE DEVELOPMENT RESOURCES

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR OBESITY TREATMENTS BY TYPE, 2014-2021 ($ MILLIONS)
    • FIGURE 1: MAIN SIGNALING AREAS TARGETED FOR OBESITY INTERVENTION
    • FIGURE 2: ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
    • FIGURE 3: PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
    • FIGURE 4: GLOBAL MARKET SHARE OF PHARMACEUTICAL DRUGS BY REGION, 2014 AND 2019
    • FIGURE 5: NUMBER OF COMMERCIALIZED OBESITY DRUGS AND DEVICE THERAPEUTICS, 2016 AND 2021 (UNITS)
    • FIGURE 6: NUMBER OF COMMERCIALIZED BARIATRIC SURGERIES MINUS BANDS AND BALLOONS, 2016 AND 2021 (UNITS)
    • FIGURE 7: NUMBER OF COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)
    • FIGURE 8: GLOBAL MARKET FOR COMMERCIALIZED OBESITY THERAPIES BY MECHANISM OF ACTION, 2016 AND 2021 (%)
    • FIGURE 9: NUMBER OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)
    • FIGURE 10: GLOBAL MARKET OF COMMERCIALIZED OBESITY TREATMENTS BY DOSING TYPE, 2016 AND 2021 (%)
    • FIGURE 11: FOUR MOST COMMON U.S. BARIATRIC PROCEDURES
    • FIGURE 12: CASE MIX OF BARIATRIC SURGERIES IN THE U.S., 2014 (%)
    • FIGURE 13: MAESTRO RECHARGEABLE SYSTEM
    • FIGURE 14: NUMBER OF COMMERCIALIZED OBESITY DEVICES*, 2016 AND 2021 (%)
Back to Top